106 related articles for article (PubMed ID: 19290944)
1. Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog.
Bonhage MR; Chilcoat CD; Li Q; Melendez V; Flournoy WS
J Vet Pharmacol Ther; 2009 Apr; 32(2):146-53. PubMed ID: 19290944
[TBL] [Abstract][Full Text] [Related]
2. Protection by a transdermal patch containing physostigmine and procyclidine of soman poisoning in dogs.
Kim WS; Cho Y; Kim JC; Huang ZZ; Park SH; Choi EK; Shin S; Nam SY; Kang JK; Hwang SY; Kim YB
Eur J Pharmacol; 2005 Nov; 525(1-3):135-42. PubMed ID: 16256978
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis against organophosphate poisoning by sustained release of scopolamine and physostigmine.
Meshulam Y; Cohen G; Chapman S; Alkalai D; Levy A
J Appl Toxicol; 2001 Dec; 21 Suppl 1():S75-8. PubMed ID: 11920924
[TBL] [Abstract][Full Text] [Related]
4. Physostigmine-induced hypothermic response in rats and its relationship with endogenous arginine vasopressin.
Yang YL; Shen ZL; Zou Q; Tang Y; Huang T
Life Sci; 2009 Oct; 85(15-16):586-91. PubMed ID: 19723529
[TBL] [Abstract][Full Text] [Related]
5. Subchronic physostigmine pretreatment in guinea pigs: effective against soman and without side effects.
Philippens IH; Busker RW; Wolthuis OL; Olivier B; Bruijnzeel PL; Melchers BP
Pharmacol Biochem Behav; 1998 Apr; 59(4):1061-7. PubMed ID: 9586868
[TBL] [Abstract][Full Text] [Related]
6. Scopolamine augments the efficacy of physostigmine against soman poisoning in guinea pigs.
Philippens IH; Melchers BP; Olivier B; Bruijnzeel PL
Pharmacol Biochem Behav; 2000 Jan; 65(1):175-82. PubMed ID: 10638651
[TBL] [Abstract][Full Text] [Related]
7. Side effects of physostigmine as a pretreatment in guinea pigs.
Philippens IH; Wolthuis OL; Busker RW; Langenberg JP; Melchers BP
Pharmacol Biochem Behav; 1996 Sep; 55(1):99-105. PubMed ID: 8870044
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic transdermal treatment with physostigmine and scopolamine against soman intoxication in guinea-pigs.
Meshulam Y; Davidovici R; Wengier A; Levy A
J Appl Toxicol; 1995; 15(4):263-6. PubMed ID: 7594194
[TBL] [Abstract][Full Text] [Related]
9. Extrapolating from animal studies to the efficacy in humans of a pretreatment combination against organophosphate poisoning.
Levy A; Cohen G; Gilat E; Kapon J; Dachir S; Abraham S; Herskovitz M; Teitelbaum Z; Raveh L
Arch Toxicol; 2007 May; 81(5):353-9. PubMed ID: 17009047
[TBL] [Abstract][Full Text] [Related]
10. Effects of physostigmine on the startle in guinea pigs: two mechanisms involved.
Philippens IH; Olivier B; Melchers BP
Pharmacol Biochem Behav; 1997 Dec; 58(4):909-13. PubMed ID: 9408195
[TBL] [Abstract][Full Text] [Related]
11. Physiological, biochemical and histological changes due to physostigmine in monkeys.
Jeevaratnam K; Dasgupta S; Pravinkumar ; Pant SC; Sachan AS; Selvamurthy W; Ray US; Mukhopadhyay S; Purkayastha SS
Indian J Physiol Pharmacol; 1998 Jan; 42(1):25-38. PubMed ID: 9513791
[TBL] [Abstract][Full Text] [Related]
12. Scopolamine bioavailability in combined oral and transdermal delivery.
Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
[TBL] [Abstract][Full Text] [Related]
13. Development and in vivo assessment of a transdermal system for physostigmine.
Benech H; Vincenti M; Fouchart F; Pruvost A; Vienet R; Istin M; Grognet JM
Methods Find Exp Clin Pharmacol; 1998; 20(6):489-98. PubMed ID: 9789873
[TBL] [Abstract][Full Text] [Related]
14. Physostigmine--an overview as pretreatment drug for organophosphate intoxication.
Somani SM; Dube SN
Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):367-87. PubMed ID: 2676871
[TBL] [Abstract][Full Text] [Related]
15. The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
Neurosci Lett; 1992 Sep; 144(1-2):79-83. PubMed ID: 1436716
[TBL] [Abstract][Full Text] [Related]
16. Stress adversely affects efficacy of physostigmine-scopolamine pretreatment against soman in guinea pigs.
Philippens IH; Joosen MJ; Vanwersch RA
Pharmacol Biochem Behav; 2005 Sep; 82(1):125-32. PubMed ID: 16126267
[TBL] [Abstract][Full Text] [Related]
17. Comparing the response surfaces of two cholinolytics when used in combination with physostigmine as a pretreatment against organophosphate challenge.
Solana RP; Gennings C; Anderson D; Carter WH; Carchman RA; Harris LW
Drug Chem Toxicol; 1989; 12(3-4):197-219. PubMed ID: 2632243
[TBL] [Abstract][Full Text] [Related]
18. Drug interaction for plasma protein binding: physostigmine and other drugs.
Somani SM; Unni LK; McFadden DL
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):412-6. PubMed ID: 3654032
[TBL] [Abstract][Full Text] [Related]
19. Development of next generation medical countermeasures to nerve agent poisoning.
Wetherell J; Price M; Mumford H; Armstrong S; Scott L
Toxicology; 2007 Apr; 233(1-3):120-7. PubMed ID: 16979808
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs.
Giacobini E; Somani S; McIlhany M; Downen M; Hallak M
Neuropharmacology; 1987 Jul; 26(7B):831-6. PubMed ID: 3658115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
